These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38896054)

  • 1. Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET).
    Baptiste PJ; Wong AYS; Schultze A; Clase CM; Leyrat C; Williamson E; Powell E; Mann JFE; Cunnington M; Teo K; Bangdiwala SI; Gao P; Tomlinson L; Wing K
    Am J Epidemiol; 2024 Jun; ():. PubMed ID: 38896054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial.
    Baptiste PJ; Wong AYS; Schultze A; Cunnington M; Mann JFE; Clase C; Leyrat C; Tomlinson LA; Wing K
    BMJ Open; 2022 Mar; 12(3):e051907. PubMed ID: 35260450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
    BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
    Natale P; Palmer SC; Navaneethan SD; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD006257. PubMed ID: 38682786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the ONTARGET and TRANSCEND studies: an update and discussion.
    Fitchett D
    Vasc Health Risk Manag; 2009; 5(1):21-9. PubMed ID: 19436659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
    White CM; Greene L
    J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease　- Propensity Score Matching Analysis.
    Kim HJ; Lee MH; Jo SH; Seo WW; Kim SE; Kim KJ; Choi JO; Ahn HS; Choi DJ; Ryu KH
    Circ J; 2019 Dec; 84(1):83-90. PubMed ID: 31776309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction.
    She J; Lou B; Liu H; Zhou B; Jiang GT; Luo Y; Wu H; Wang C; Yuan Z
    ESC Heart Fail; 2021 Dec; 8(6):4607-4616. PubMed ID: 34664407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
    Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
    Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.
    Mansfield KE; Nitsch D; Smeeth L; Bhaskaran K; Tomlinson LA
    BMJ Open; 2016 Dec; 6(12):e012690. PubMed ID: 28003286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.